Amrita Krishnan, MD
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at the City of Hope in Duarte, California, told The ASCO Post that the most exciting drug in the “New Agents” session she moderated at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition was venetoclax (Venclexta).
“I am most impressed with this drug. As targeted therapy, it’s exceptional. It has single-agent activity, although clearly there is a rationale for adding dexamethasone, and it’s well tolerated,” Dr. Krishnan said. “I have personally used venetoclax in patients with very advanced, refractory disease and have seen amazing responses.” ■
Disclosure: Dr. Krishnan has been on the speaker bureau and consulted for Celgene, Takeda, Janssen, and Onyx.
Higher response rates and deeper responses [to venetoclax] were seen in patients with t(11;14), vs those without this translocation.— Shaji Kumar, MD
Early-phase studies suggest that venetoclax (Venclexta) holds promise as a treatment for myeloma. At the 2016 American...!-->!-->